Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    mRNA and next-gen vaccines in 2026: a crash course

    mRNA vaccines and RNA drugs give the body genetic instructions, or silence faulty ones, instead of delivering a finished protein or small molecule.[1][2] As of October 2026 the field has its first mRNA flu vaccine, a positive phase 3 trial for a personalised mRNA cancer therapy, and US policy changes, including narrower COVID-19 vaccine labels and a court stay of federal vaccine advisory committee votes that is under appeal.[3][4][5][6][7]

    Editor reviewedStrict sourcingUpdated mRNA and next-gen vaccinesHealth and medicineLife sciences

    Why the field matters

    Most medicines are a finished molecule. An mRNA vaccine is a set of instructions instead. It tells your cells how to make one harmless protein, such as part of a virus, so the immune system learns to recognise it.[1] The mRNA does not change your DNA, and the cell breaks it down.[8] RNA drugs such as siRNAs work the other way around. They switch off the message for a harmful protein.[2]

    Speed is a big reason the field matters. The first mRNA COVID-19 vaccine was authorised in just under a year. Later versions updated for new strains took as little as two to three months.[9]

    RNA medicines split into two broad classes. Expression platforms (non-replicating mRNA and self-amplifying RNA) deliver an open reading frame for an antigen or therapeutic protein.[1] Silencing platforms (siRNA and antisense oligonucleotides) reduce expression of a target transcript through RISC or RNase H1.[10][11] Expression platforms are attractive because changing the antigen means changing a sequence, and in vitro transcription gives high yields.[12] CEPI notes that strain-updated COVID-19 vaccines were authorised in as little as two to three months.[9]

    Map of the field

    Key ideas

    The 2023 Nobel Prize recognised the discovery that chemically modified nucleosides make synthetic mRNA usable as a vaccine.[23] Modification dampens the innate immune alarm that unmodified RNA can trigger.[24] Delivery is the second key idea. Ionizable lipids carry RNA into cells and release it from the endosome.[25] For silencing drugs, GalNAc sugars carry oligonucleotides into liver cells without a nanoparticle.[18]

    Main players

    Moderna and BioNTech are the leading mRNA companies. Moderna has four FDA-approved products, including the RSV vaccine mRESVIA (2024) and the COVID-19 vaccine mNEXSPIKE (2025).[3][26][27] BioNTech developed Comirnaty with Pfizer and agreed to buy CureVac; the exchange offer met its closing conditions in December 2025.[5][28] Alnylam leads RNAi. Its drug Amvuttra brought in more than $1 billion in the second quarter of 2026.[29] CSL and Arcturus market the self-amplifying vaccine Kostaive.[17] CEPI funds preparedness work, including a phase 3 trial of Moderna’s H5 bird-flu vaccine candidate.[30]

    The frontier in October 2026

    • Beyond COVID. The FDA approved mFLUSIVA in August 2026, after first refusing to file the application in February.[3][31] Moderna’s norovirus vaccine missed an early-success test at a phase 3 interim analysis.[32]
    • Cancer. INTerpath-001 was the first positive late-stage result for an mRNA cancer treatment.[33]
    • RNA drugs. RNAi has moved into heart disease. Amvuttra was approved for ATTR cardiomyopathy in 2025.[34]
    • Policy. In 2025 the FDA narrowed COVID-19 vaccine labels and HHS ended 22 BARDA mRNA investments.[5][35] In March 2026 a federal court stayed the appointments and votes of the reconstituted ACIP, the federal vaccine advisory committee; the government has appealed.[6][7] On 27 August 2026 the FDA approved XFG-targeted 2026-2027 COVID-19 vaccines, keeping the narrower eligibility.[36][37] States have moved in both directions: bills to ban or limit mRNA vaccines were introduced in at least seven states in 2025, while several states changed laws in 2026 to rely less on ACIP.[38][39] See the policy debate and the tracker.

    This page describes evidence and regulatory status. It is not medical advice.

    Questions readers ask

    Is there an approved mRNA flu vaccine?

    Yes. In August 2026 the FDA approved Moderna's mFLUSIVA for adults 50 and older, the first mRNA-based influenza vaccine. Approval for people 65 and older is accelerated approval that depends on a confirmatory trial.[3][40]

    Has a personalised mRNA cancer vaccine worked in a large trial?

    In August 2026 Merck and Moderna reported that intismeran autogene plus pembrolizumab met its primary endpoint in the phase 3 INTerpath-001 melanoma trial. The data were to be shared with regulators, and no approval had been announced.[4][41]

    Does mRNA from a vaccine change a person's DNA?

    A foundational review describes mRNA as a non-integrating platform that normal cellular processes break down.[8]

    What is the difference between an mRNA vaccine and an siRNA drug?

    An mRNA vaccine delivers instructions so cells make a protein. An siRNA drug such as Onpattro silences the mRNA that encodes a disease-causing protein.[1][2]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      Two major types of RNA are studied as vaccines, non-replicating mRNA and virally derived self-amplifying RNA. confirmedas of 2018-01-12

    2. [2]

      On 10 August 2018 the FDA approved Alnylam's Onpattro (patisiran), the first approved RNAi therapeutic, which silences the mRNA encoding transthyretin to treat hereditary ATTR amyloidosis polyneuropathy. confirmedas of 2018-08-10

    3. [3]

      In August 2026 the FDA approved Moderna's mFLUSIVA (mRNA-1010) for adults 50 and older, the first mRNA-based influenza vaccine and Moderna's fourth FDA-approved product after Spikevax, mRESVIA and mNEXSPIKE. confirmedas of 2026-08-06

    4. [4]

      On 19 August 2026 Merck and Moderna reported that the phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in resected high-risk melanoma. confirmedas of 2026-08-19

    5. [5]

      In August 2025 the FDA limited the approved use of Pfizer-BioNTech's Comirnaty to people 65 and older and younger people with at least one condition that puts them at high risk of severe COVID-19. confirmedas of 2025-08-25

    6. [6]

      On 16 March 2026 a federal district court in Massachusetts, in American Academy of Pediatrics v. Kennedy, stayed the 13 ACIP appointments and all votes of the reconstituted committee since June 2025. confirmedas of 2026-03-17

    7. [7]

      The federal government appealed the March 2026 ruling to the First Circuit (No. 26-1503), and district court proceedings were paused pending the appeal. confirmedas of 2026-09-30

    8. [8]

      mRNA is a non-infectious, non-integrating platform that is degraded by normal cellular processes. confirmedas of 2018-01-12

    9. [9]

      CEPI's 2027-2031 strategy notes that the first mRNA COVID-19 vaccine was authorised in just under a year and later strain-updated vaccines in as little as two to three months. confirmedas of 2026-02-01

    10. [10]

      Oligonucleotides can also act through the RNA-induced silencing complex (RISC), whose AGO2 enzyme cleaves or blocks translation of the matching mRNA. confirmedas of 2026-02-01

    11. [11]

      Many ASOs work by forming a DNA-RNA duplex with their target, which the enzyme RNase H1 recognises and cleaves, reducing production of the encoded protein. confirmedas of 2026-02-01

    12. [12]

      mRNA vaccines can potentially be manufactured rapidly, cheaply and at scale, mainly because in vitro transcription reactions give high yields. confirmedas of 2018-01-12

    13. [13]

      The first authorized mRNA COVID-19 vaccines, Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273, both encode the SARS-CoV-2 spike protein and are formulated in lipid nanoparticles. confirmedas of 2023-03-01

    14. [14]

      Lipid nanoparticles used for mRNA delivery usually contain four components, an ionizable lipid, a PEG-linked lipid, cholesterol and a phospholipid (helper lipid). confirmedas of 2023-03-01

    15. [15]

      Lipid nanoparticles in the blood adsorb apolipoprotein E and therefore accumulate preferentially in the liver, which limits delivery to other organs. confirmedas of 2023-03-01

    16. [16]

      Self-amplifying RNA encodes both the antigen and viral replication machinery, which lets the RNA copy itself inside the cell and produce abundant protein. confirmedas of 2018-01-12

    17. [17]

      On 14 February 2025 the European Commission authorized CSL and Arcturus Therapeutics' Kostaive (ARCT-154), the first self-amplifying mRNA COVID-19 vaccine approved in the EU, for adults 18 and older. confirmedas of 2025-02-14

    18. [18]

      GalNAc is a sugar attached to oligonucleotides that binds the asialoglycoprotein receptor on liver cells and drives efficient uptake into hepatocytes. confirmedas of 2026-02-01

    19. [19]

      A February 2026 review counted sixteen antisense oligonucleotide drugs approved by the US FDA and the European Medicines Agency. confirmedas of 2026-02-01

    20. [20]

      Each intismeran dose is a synthetic mRNA encoding up to 34 neoantigens chosen from the mutations in that patient's own tumour. confirmedas of 2026-08-19

    21. [21]

      The 100 Days Mission, articulated by CEPI in 2021, is the goal of developing safe, effective and accessible vaccines within 100 days of identifying a new pandemic threat. confirmedas of 2026-02-01

    22. [22]

      The World Health Assembly adopted the WHO Pandemic Agreement in May 2025, but it cannot open for signature until its annex on pathogen access and benefit sharing (PABS) is finalised. confirmedas of 2026-05-19

    23. [23]

      The 2023 Nobel Prize in Physiology or Medicine was awarded to Katalin Karikó and Drew Weissman for discoveries on nucleoside base modifications that enabled effective mRNA vaccines against COVID-19. confirmedas of 2023-10-02

    24. [24]

      Chemically modified nucleosides in synthetic mRNA partially suppress recognition of double-stranded RNA and reduce type I interferon signalling, an innate immune alarm response. confirmedas of 2018-01-12

    25. [25]

      Inside the acidic endosome, ionizable lipids become positively charged and pair with the endosome's own lipids, disrupting its membrane and releasing the RNA into the cytoplasm. confirmedas of 2023-03-01

    26. [26]

      The FDA approved Moderna's RSV vaccine mRESVIA effective 31 May 2024 for adults 60 and older. confirmedas of 2024-05-31

    27. [27]

      On 30 May 2025 the FDA approved Moderna's next-generation COVID-19 vaccine mNEXSPIKE for previously vaccinated people aged 65 and older, or aged 12-64 with at least one condition that puts them at high risk of severe COVID-19. confirmedas of 2025-05-30

    28. [28]

      On 3 December 2025 BioNTech announced that about 81.74% of CureVac shares had been tendered in its exchange offer and that all closing conditions for the acquisition had been satisfied. confirmedas of 2025-12-03

    29. [29]

      Alnylam reported second-quarter 2026 net product revenues of about $1.17 billion, of which Amvuttra contributed about $1.01 billion. confirmedas of 2026-07-30

    30. [30]

      In December 2025 CEPI agreed to provide up to $54.3 million for a phase 3 trial of Moderna's H5 pandemic influenza vaccine candidate mRNA-1018, and Moderna committed 20% of its H5 vaccine capacity to low- and middle-income countries at affordable prices. confirmedas of 2025-12-18

    31. [31]

      In February 2026 the FDA first refused to file Moderna's flu vaccine application, citing the choice of comparator vaccine for older adults rather than safety or efficacy concerns, then accepted an amended application about a week later. confirmedas of 2026-02-18

    32. [32]

      Moderna's norovirus vaccine candidate mRNA-1403 did not meet the statistical criteria for early success at a phase 3 interim analysis, the company reported in July 2026. confirmedas of 2026-07-31

    33. [33]

      INTerpath-001 was described as the first positive late-stage result for an mRNA-based cancer treatment and for an individualized neoantigen therapy. confirmedas of 2026-08-19

    34. [34]

      On 20 March 2025 the FDA approved Alnylam's RNAi drug Amvuttra (vutrisiran) for the cardiomyopathy of transthyretin amyloidosis (ATTR-CM), based on the phase 3 HELIOS-B trial, with quarterly subcutaneous dosing. confirmedas of 2025-03-20

    35. [35]

      In August 2025 HHS announced that BARDA was terminating 22 mRNA vaccine development investments worth about $500 million. confirmedas of 2025-08-08

    36. [36]

      On 27 August 2026 the FDA approved 2026-2027 formula versions of the mRNA vaccines Comirnaty, Spikevax and mNEXSPIKE, which target the XFG variant; Novavax's protein-based Nuvaxovid was also approved for the season. confirmedas of 2026-08-27

    37. [37]

      The 2026-2027 approvals kept the narrower US eligibility set in 2025, covering everyone 65 and older plus younger people with at least one high-risk condition, from age 5 for Comirnaty, 6 months for Spikevax and 12 for mNEXSPIKE. confirmedas of 2026-08-28

    38. [38]

      In 2025 Republican lawmakers in at least seven states introduced bills to ban or limit mRNA vaccines; some would have imposed criminal penalties, fines or licence revocation on clinicians who gave the shots. confirmedas of 2025-04-14

    39. [39]

      According to the Association of State and Territorial Health Officials, in 2026 Colorado, Connecticut, Maine, Maryland, New Mexico, Oregon, Vermont and Washington enacted laws modifying ACIP's role in state vaccine policy, several of them requiring insurers to cover vaccines recommended by bodies other than ACIP. reportedas of 2026-05-25

    40. [40]

      The FDA granted mFLUSIVA standard approval for ages 50-64 and accelerated approval for 65 and older, the latter conditional on a confirmatory trial. confirmedas of 2026-08-06

    41. [41]

      Merck and Moderna said the INTerpath-001 data would be presented at a medical meeting and shared with regulatory authorities; no approval decision had been announced as of the announcement. confirmedas of 2026-08-19

    Revision history (2)
    1. Page created.
    2. Added the 2026-2027 COVID-19 vaccine approvals and state legislation to the frontier section.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "mRNA and next-gen vaccines in 2026: a crash course." ContentLora, updated Oct 10, 2026. https://contentlora.com/explain/vaccines-mrna

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents